Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9376279 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HSD17B10HPGDKDM4EMYC | |
| SCHEMBL17424942 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HSD17B10HPGDKDM4EKMT2A | |
| SCHEMBL2397071 | 0.79 | CYP1A2 (0.44) | ALDH1A1HSD17B10HPGDKDM4EKMT2A | |
| SCHEMBL954804 | 0.79 | TSHR (0.41) | ALDH1A1KDM4EKMT2ACYP1A2MEN1 | |
| SCHEMBL668028 | 0.79 | HTT (0.49) | ALDH1A1HSD17B10HPGDKDM4EKMT2A | |
| SCHEMBL1549077 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HPGDKDM4EMYC | |
| SCHEMBL5963706 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HPGDKDM4EMYC | |
| SCHEMBL4886689 | 0.78 | ALOX15 (0.41) | ALDH1A1HSD17B10MYCLMNAALOX15 | |
| SCHEMBL27540363 | 0.77 | HMGB1 (0.38) | ALDH1A1HSD17B10HPGDMYCKMT2A | |
| SCHEMBL7025449 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HSD17B10HPGDKDM4EMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966190-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007071348-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071348-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | CYP3A5, CYP3A43, CYP3A4 | ALDH1A1 198/4885HSD17B10 1139/4885HPGD 483/4885 |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | ALDH1A1 4840/4885HSD17B10 4785/4885HPGD 826/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | ALDH1A1 65/4885HSD17B10 617/4885HPGD 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.